FDA warned New Green Nutrition that its diabetes products were unapproved new drugs and one contained prescription glyburide sold without a prescription.
What happened
In August 2021, FDA reviewed www.newgreenusa.com and linked Facebook and Twitter pages and found the company took orders for Xiao Ke Wan, Diabetee-Care, and Specific Jiang Tang Remedy. FDA said website, social media, and label claims about blood sugar and diabetes made the products drugs, but they lacked FDA approval and adequate directions for safe lay use. FDA also said Xiao Ke Wan's label lists glibenclamide (glyburide), a prescription blood sugar drug, and it was offered without a prescription.
What FDA found
FDA said the products are drugs because website and label claims say they treat or affect blood sugar and diabetes.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)FDA said the products are unapproved new drugs because no FDA-approved applications are in effect for them.
FD&C Act sections 505(a), 301(d), 21 U.S.C. 355(a), 331(d)FDA said the products are misbranded because their labeling lacks adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5FDA said Xiao Ke Wan's label lists glibenclamide (glyburide), a prescription blood sugar drug, and the product was offered without a prescription.
FD&C Act section 503(b)(1), 301(k), 21 U.S.C. 353(b)(1), 331(k)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, with documentation, or explain why it cannot and when it will.
Who should pay attention
- retailers and online marketplaces that sell herbal diabetes products
- distributors and brands that buy supplements from New Green Nutrition
- consumers using unapproved blood sugar products
This is a summary. Read the original letter on fda.gov.